Does UnitedHealthcare Cover Zepbound? OptumRx Decisions, Plan Variants, and Appeals

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• UHC routes all Zepbound prior authorization decisions through OptumRx, its in-house pharmacy benefit manager
• Coverage varies sharply across UHC Choice, Choice Plus, Navigate, Surest, AARP Medicare Advantage, and self-funded employer plans
• Self-funded employers using UHC as TPA frequently carve out AOM benefits, defeating PA at the benefits level
• The OSA indication is the strongest path for previously-denied patients who have documented sleep apnea
• Realistic fallback paths are Lilly Direct self-pay ($499/mo) or compounded tirzepatide ($199-$399/mo)

Direct answer

UnitedHealthcare covers Zepbound on its standard commercial formulary at Tier 3 with prior authorization through OptumRx. As of May 2026, confirm with your specific plan. Coverage depends on three variables: whether your employer plan includes AOM benefits, whether OptumRx approves the PA based on BMI and comorbidity documentation, and whether step therapy applies. AARP Medicare Advantage and other UHC Medicare plans generally do not cover Zepbound for weight loss; some cover for OSA after the 2024 FDA approval. Denied patients have appeals, the OSA pathway, Lilly Direct self-pay, or compounded tirzepatide as alternatives.

Table of contents

1. UHC and OptumRx: how the decision actually works
2. Plan-by-plan: UHC Choice, Choice Plus, Navigate, Surest, and self-funded
3. OptumRx PA criteria for Zepbound
4. Denial codes you might see
5. The appeal that gets approvals overturned
6. The OSA pathway through UHC
7. AARP Medicare Advantage rules
8. Cost scenarios by plan type
9. When to move to self-pay options
10. FAQ
11. Sources

UHC and OptumRx: how the decision actually works

OptumRx is a wholly-owned subsidiary of UnitedHealth Group, the parent of UnitedHealthcare. When UHC patients submit a prior authorization for Zepbound, the request enters the OptumRx queue. Clinical reviewers at OptumRx apply the formulary criteria; the approval or denial returns to the patient's pharmacy.

The relationship is operationally tighter than Cigna/Express Scripts or BCBS/Prime Therapeutics. OptumRx and UHC share systems, claims data, and clinical staff. For patients this means the appeal address and timeline are predictable: appeals route to OptumRx Clinical Review with the standard 30-day commercial response window.

Surest (a UHC plan type that consolidated former Bind Benefits) operates somewhat differently. Surest plans show patients a single fixed price for each medication rather than tier structures. Zepbound under Surest displays a specific dollar amount per fill, but the underlying PA still routes through OptumRx.

Plan-by-plan: UHC Choice, Choice Plus, Navigate, Surest, and self-funded

UHC plan type	Zepbound coverage pattern	Notable detail
UHC Choice	Tier 3 with PA	Standard HMO; typical step therapy
UHC Choice Plus	Tier 3 with PA	PPO-style network; same formulary
UHC Navigate	Tier 3 with PA, gatekeeper PCP	Requires PCP referral for specialist prescribers in many setups
UHC Surest	Fixed-dollar coverage shown	Pricing transparent; PA still required
AARP Medicare Complete	Not covered for weight loss	OSA pathway available on some plans
Self-funded UHC TPA plans	Varies by employer	AOM carve-outs common; benefits-level decision
UHC Community Plan (Medicaid)	Varies by state contract	Roughly 14 states allow GLP-1 AOM coverage in Medicaid

The "Choice" vs "Choice Plus" distinction is about network design, not formulary. Both use the OptumRx formulary. Navigate adds a referral requirement that affects which prescribers can write Zepbound efficiently.

OptumRx PA criteria for Zepbound

The published OptumRx commercial PA criteria for Zepbound (current May 2026):

• BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, CVD, OSA)
• Documented 6-month trial of comprehensive lifestyle intervention
• Prescriber attestation of continued lifestyle counseling alongside medication
• Age ≥ 18
• No concurrent GLP-1 agonist
• Step therapy may apply (plan-specific): trial of Saxenda, Wegovy, or phentermine before Zepbound
• Reauthorization: ≥ 5% weight loss from baseline at 6 months

OptumRx tends to be stricter than peers on the "6-month documented lifestyle intervention" element. Vague language ("the patient has tried diet and exercise") gets denied. Specific intervention descriptions ("the patient participated in a structured medical weight management program from January to June 2025, including monthly visits, food log review, and exercise prescription") get approved.

Denial codes you might see

• Code MEDC-01 (clinical criteria not met): BMI or comorbidity documentation issue
• Code STEP-02 (step therapy required): Prior alternative not documented
• Code BENEFIT-04 (not a covered benefit): Employer plan AOM exclusion
• Code QL-05 (quantity limit exceeded): Prescription quantity outside formulary parameters
• Code DUP-06 (duplicate therapy): Patient has active claim for another GLP-1

The denial code on the letter is the most important data point in the entire denial. It tells you whether the appeal should be clinical (codes 01, 05, 06), procedural (codes 02), or benefits-level (code 04). Treat the code as your appeal-strategy compass.

The appeal that gets approvals overturned

Strong UHC/OptumRx appeals include:

1. Patient-specific clinical context. Three or more BMI measurements across time, baseline weight, weight trajectory, and the failed prior interventions in chronological detail.
2. Comorbidity diagnoses with ICD-10 codes. Vague mentions of "high blood pressure" do not count. Use I10 for essential hypertension, E78.5 for hyperlipidemia, E11.65 for T2D with hyperglycemia, G47.33 for OSA.
3. Specific lifestyle-intervention documentation. Name the program, dates, and what was attempted. Generic "diet and exercise tried" appeals get denied a second time.
4. Clinical trial citation. Reference SURMOUNT-1 (Jastreboff et al. 2022, NEJM): mean 22.5% weight loss at 15 mg over 72 weeks. For OSA cases, cite SURMOUNT-OSA (Malhotra et al. 2024, NEJM).
5. Letter of medical necessity in clinical prose. Avoid templates. The reviewer at OptumRx is a clinician and responds to clinical reasoning.

Industry benchmark data suggests OptumRx overturns roughly 35-45% of well-constructed GLP-1 first-level appeals. The biggest factor is documentation completeness, not the medication's clinical merit.

The OSA pathway through UHC

The December 2024 FDA approval of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity created a coverage path that may bypass UHC plan AOM exclusions.

Requirements for the OSA pathway:

• Documented OSA diagnosis: polysomnography or home sleep apnea test showing AHI ≥ 15 events/hour
• BMI ≥ 30
• ICD-10 G47.33 (obstructive sleep apnea) on the prescription and PA
• Trial or documented contraindication to CPAP therapy (varies by plan)

UHC updated OSA criteria for most commercial plans during Q1 2025. Self-funded employer plans had varying adoption timelines; check before assuming the OSA path is available.

The SURMOUNT-OSA trial (Malhotra et al. 2024) provides the clinical basis: tirzepatide reduced the apnea-hypopnea index by approximately 25 events/hour versus 5 events/hour with placebo. This is the citation to include in any OSA-indication PA.

AARP Medicare Advantage rules

AARP-branded Medicare Advantage prescription drug plans are administered by UnitedHealthcare and follow CMS Part D rules. The Medicare statute prohibits Part D coverage of weight-loss medications.

The 2024 FDA approval of Zepbound for OSA created a partial path. Some AARP MA-PD plans began covering Zepbound for OSA in Q2 2025 with the following requirements:

• OSA diagnosis with sleep study (AHI ≥ 15)
• BMI ≥ 30
• Trial of CPAP or documented intolerance
• Prescription explicitly under the OSA indication, ICD-10 G47.33

For AARP MA members seeking Zepbound for weight loss alone: no Part D plan covers this regardless of clinical merit, until Congress changes the underlying Medicare statute.

Cost scenarios by plan type

Scenario	Monthly OOP	Notes
UHC Choice/Choice Plus, Tier 3 fixed copay	$40-$80	Standard commercial
UHC Surest fixed-dollar pricing	~$100-$200	Plan-specific; transparent before fill
UHC with Lilly savings card (eligible plans)	$25	Card stacks with coverage
UHC HDHP before deductible	~$1,086 retail	Until annual deductible met
AARP MA-PD (OSA pathway)	$47-$100 Tier copay	Plan-specific
Self-funded UHC plan, AOM excluded	Cash pay only	-
Lilly Direct vials, no coverage	$499	LillyDirect.com self-pay program
Compounded tirzepatide (503A)	$199-$399	Not FDA-approved; not covered by insurance

When to move to self-pay options

The realistic triggers for moving from UHC pursuit to self-pay:

• Internal appeals have been denied and external review unlikely to overturn
• Employer plan AOM exclusion is permanent and no OSA pathway applies
• The PA is approvable but the copay/coinsurance exceeds Lilly Direct's $499/mo
• The patient cannot tolerate the step-therapy alternative and exception was denied

Lilly Direct ($499/mo for single-dose vials) is the FDA-approved self-pay option. Compounded tirzepatide ($199-$399/mo through licensed 503A pharmacies) is cheaper but is not FDA-approved and is not therapeutically equivalent to Zepbound.

Contrary view: when to keep fighting the UHC system

It's easy to abandon a UHC denial after one round. Many patients shouldn't.

Three reasons to persist:

• OptumRx's first-pass clinical reviewers apply criteria mechanically. Second-pass medical director review weighs clinical narrative more heavily.
• External review by an independent third-party often favors patients when the denial is procedural rather than clinical.
• The OSA pathway opened a new approval route mid-2025 that some patients have not yet utilized.

If you have documented OSA but were denied under the weight-loss indication, the path forward is not always "appeal the weight-loss denial." Sometimes it is "withdraw and resubmit under the OSA indication."

Decision framework

If you're submitting a UHC PA for the first time: Include three-or-more BMI measurements, ICD-10 comorbidity codes, and specific lifestyle intervention documentation. Avoid template language.

If you were denied: Read the code. MEDC-01 needs clinical narrative. STEP-02 needs an exception request. BENEFIT-04 is a benefits-level conversation, not a clinical one.

If your plan excludes AOM but you have OSA: Withdraw the weight-loss PA. Resubmit under the OSA indication with sleep-study documentation.

If self-pay is the answer: Compare Lilly Direct ($499/mo, FDA-approved) vs compounded tirzepatide ($199-$399/mo, not FDA-approved).

FAQ

Does UnitedHealthcare cover Zepbound? On the standard commercial formulary, yes, at Tier 3 with PA. Coverage depends on employer plan design and PA approval.

Who decides my Zepbound PA? OptumRx, UHC's wholly-owned PBM. The decision is procedurally separate from your UHC plan but operationally tightly integrated.

What does Zepbound cost with UHC coverage? $40-$80 monthly copay typically; $25 with Lilly savings card.

Why was my PA denied? Most common: BMI documentation gap, comorbidity coding issue, AOM exclusion in employer plan, or step therapy not met. The denial code on the letter tells you which.

Does AARP Medicare Advantage cover Zepbound? Not for weight loss. Some plans cover for OSA after the 2024 FDA approval.

Does Surest cover Zepbound? Surest shows fixed-dollar pricing for Zepbound where covered. PA still applies. Check your specific Surest plan before assuming.

How do I appeal? Submit within 180 days of denial. Include BMI history, ICD-10 codes, lifestyle intervention specifics, SURMOUNT-1 citation, and a letter of medical necessity.

Does UHC cover compounded tirzepatide? No. Compounded medications are not FDA-approved.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022.
2. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea and Obesity. NEJM. 2024.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction. JAMA. 2024.
4. UnitedHealthcare commercial drug formulary. 2026 edition.
5. OptumRx clinical formulary management policy. 2026.
6. FDA. Zepbound prescribing information. Updated 2024.
7. FDA. Approval of tirzepatide for obstructive sleep apnea. December 2024.
8. Centers for Medicare & Medicaid Services. Part D drug coverage rules. Updated 2025.
9. Eli Lilly. LillyDirect self-pay program. Accessed May 2026.
10. Surest plan benefit design overview. UHC documentation 2026.
11. NCQA. Step-therapy protocol exception requirements. 2024.
12. The Obesity Society. Position statement on AOM coverage barriers. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational information about insurance coverage and connects patients with independent licensed providers. We do not administer insurance plans or guarantee coverage decisions. All claims handling and PA decisions belong to your plan and its pharmacy benefit manager.

Compounded Medication Notice. Compounded tirzepatide is prepared by a state-licensed 503A pharmacy in response to a valid individual prescription. The compounded product is not FDA-approved and is not interchangeable with Zepbound. UnitedHealthcare and OptumRx do not cover compounded medications.

Results Disclaimer. The cost figures, PA outcomes, and approval rates referenced are general and do not predict your specific result. Plan benefits change annually and may change mid-year for safety or formulary reasons.

Trademark Notice. Zepbound is a registered trademark of Eli Lilly and Company. UnitedHealthcare, OptumRx, AARP Medicare Complete, and Surest are registered trademarks of their respective owners (UnitedHealth Group, AARP). FormBlends has no business relationship with UnitedHealthcare, OptumRx, Eli Lilly, or AARP.